A Young Woman's View of Flibanserin ("Pink Viagra"), FSD, and Pharma | Pharmaguy's Insights Into Drug Industry News | Scoop.it
The push for flibanserin and its treatment of hypoactive sexual dysfunction disorder in women not only makes a mockery of the drug approval process. It marks a dangerous emboldening of the trend towards medicalizing women’s sexuality and a step away from women’s equality in the bedroom.


FSD [Female Sexual Dysfunction] is a textbook example of pharmaceutical company disease-mongering. By creating FSD and promoting a medicalized view of women’s sexuality, pharmaceutical companies successfully established a market for drugs to treat low desire in women. The greatest offense, however, is the lack of scientific data and research backing FSD, a condition whose legitimacy is shaky at best. In fact, there is still very little that is known about the biological processes governing women’s sexuality.


Let’s not let Big Pharma fundamentally change how we view our bodies and sex lives. Let’s refuse to settle for a pill that denies us the emancipatory process of engaging in a much needed conversation and reconceptualizing of sexual desire in all genders.


The worst side effect of all is the drug’s association of loss of desire with a female dysfunction. Not only does this fault women for unfulfilling sexual unions, it treats sexual desire as an individual phenomenon that is gifted to someone else rather than something to be cocreated through partnership. Even the model of consent that is frequently taught continues to view sexual desire as something that is requested and then given, often a woman’s acceptance to a man’s invitation.